Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $324,907.20 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille Bedrosian sold 10,028 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.40, for a total transaction of $324,907.20. Following the sale, the insider directly owned 278,064 shares in the company, valued at $9,009,273.60. The trade was a 3.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ AMLX opened at $32.63 on Thursday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $10.83 and a 1 year high of $41.14. The stock has a market capitalization of $3.64 billion, a P/E ratio of -22.82 and a beta of -0.13. The company’s 50-day moving average is $26.60 and its 200 day moving average is $19.26.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $158,534,000. GSA Capital Partners LLP bought a new stake in Amylyx Pharmaceuticals in the second quarter worth $705,000. Dimensional Fund Advisors LP boosted its holdings in Amylyx Pharmaceuticals by 17.1% in the first quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company’s stock worth $12,544,000 after acquiring an additional 131,944 shares in the last quarter. Elmind Capital LP purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth $2,011,520. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth $12,949,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AMLX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. HC Wainwright increased their price objective on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Citigroup boosted their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Guggenheim upped their target price on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $38.86.

About Amylyx Pharmaceuticals